IDH2 and acute myeloid leukemia: Here, the direct use of hypomethylating agents combined with Venetoclax may also be an effective alternative, especially because NPM1mut AML (especially in combination with an IDH2-Mutation) reflects and specifically sensitive subgroup for this therapy26.